-

RION AESTHETICS Wins Octane LaunchPad SBDC Judges Award at Aesthetics Tech Summit

  • RION AESTHETICS awarded top presenting company by Judges at Aesthetics Tech Summit
  • Octane amplifies capital funding strategy for MedTech companies with its Top 5 SBDC ranked accelerator, LaunchPad
original Alisa Lask, RION CCO presents to Octane Judging panel. Photo courtesy of Octane SBDC. (Photo: Business Wire)

Alisa Lask, RION CCO presents to Octane Judging panel. Photo courtesy of Octane SBDC. (Photo: Business Wire)

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--RION AESTHETICS, a regenerative medicine company pioneering the use of platelet exosomes for skin care and restorative clinical applications, received the prestigious LaunchPad SBDC Judges Award at the 2022 Aesthetics Tech Summit.

“It was an honor to present our groundbreaking technologies to leading physicians, aesthetic experts, investors, and entrepreneurs,” said Alisa Lask, Chief Commercial Officer of RION. “We are thrilled to be the first and only Aesthetics company offering platelet-derived exosomes for use in skincare as well as actively developing restorative clinical applications.

Out of 65 Octane LaunchPad SBDC companies only 7 were selected as finalists using objective scoring methodology that has been in practice for 10+ years. This elite group of companies developing innovative aesthetic technologies, unveiled their technologies in front of a panel of independent judges.

“We are proud to recognize future luminaries as they lead Aesthetics into new areas,” said Director of LaunchPad SBDC, Mike Hill. “Octane and LaunchPad SBDC are thrilled to help assist these companies and most importantly amplify their capital funding structure as they enter this Aesthetic beloved space. We look forward to watching RION AESTHETICS in the coming years.”

About RION AESTHETICS

RION AESTHETICS is a regenerative medicine company, pioneering the use of platelet exosomes for skin care and restorative clinical applications. Backed by over 15 years of visionary science, we aim to transform skincare through the introduction of Plated™ SkinScience, leveraging the power of exosomes to address the most persistent skin challenges. Beyond skincare, RION AESTHETICS is pursuing FDA approval for Regenosomes, the first room-temperature stable off-the-shelf regenerative exosome that drives soft tissue healing, with the ability to address unmet needs in aesthetics medicine for applications in hair loss, regenerative tissue fillers, and topical nano-toxin technology. Visit www.rionaesthetics.com

About OCTANE

Octane convenes and enables the Southern California tech and medtech business ecosystem by connecting people, resources, and capital. We impact our community through LaunchPad, a top-performing accelerator, Capital & Growth, a platform to provide companies capital and growth resources, Ignite Series, providing leading content, and Octane Foundation for Innovation, focused on furthering our mission while advancing diversity and inclusiveness. Learn more at octaneoc.org

Contacts

Jodi Brichan, media@riontx.com

Industry:

RION AESTHETICS

Release Summary
RION AESTHETICS wins Octane LaunchPad SBDC Judges Award at Aesthetics Tech Summit
Release Versions
English
Hashtags
#AgeDefying
#BeautyFromWithin
#BeautyRoutine
#EvolutionOfInnovation
#Exosomes
#GlowGoals
#GlowySkin
#Innovation
#LuxurySkincare
#Plated
#PlatedSkinScience
#Platelet
#PlateletDerived
#PlateletDerivedExosome
#Platelets
#RegMed
#Regenosome
#RionAesthetics
#SelfCare
#SkinGoals
#SkinScience
#SkincareLover
#SkincareObsessed
#SkincareRegime
#SkincareTips

Contacts

Jodi Brichan, media@riontx.com

Social Media Profiles
@rionaesthetics
Rion Aesthetics
More News From RION AESTHETICS

INTENT Biologics Receives FDA Agreement Granting a Full Waiver for its Pediatric Study Plan for PEP Biologic™ in Advanced Wound Care

ROCHESTER, Minn.--(BUSINESS WIRE)--INTENT Biologics, a clinical-stage biotechnology company developing PEP Biologic as the first-in-class exosome-based biologic therapies for serious conditions with significant unmet medical need, announced today that the U.S. Food and Drug Administration (FDA) has agreed to INTENT’s Initial Pediatric Study Plan (iPSP) for PEP Biologic™ under IND 019567, supporting the company’s request for a full pediatric waiver for its forthcoming Biologics License Applicati...

INTENT Biologics Receives FDA Fast Track Designation for PEP Biologic™

ROCHESTER, Minn.--(BUSINESS WIRE)--INTENT Biologics, a clinical-stage biotechnology company developing first-in-class exosome-based biologic therapies for serious conditions with significant unmet medical need, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for PEP Biologic™ for the treatment of diabetic foot ulcers (DFU) under IND 019567. FDA Fast Track designation is designed to facilitate the development and expedite the review of drugs an...

CORRECTING and REPLACING RION Launches RION Vet to Transform Animal Health with First-in-Class Biologic Therapeutic; Appoints Industry Leader Mark Herthel as CEO; Announces Series A Fulfillment

ROCHESTER, Minn.--(BUSINESS WIRE)--Please replace the release with the following corrected version due to multiple revisions. The updated release reads: RION LAUNCHES RION VET TO TRANSFORM ANIMAL HEALTH WITH FIRST-IN-CLASS BIOLOGIC THERAPEUTIC; APPOINTS INDUSTRY LEADER MARK HERTHEL AS CEO; ANNOUNCES SERIES A FULFILLMENT RION, a clinical-stage regenerative medicine company and global leader in exosome-based therapeutics, today announced the formation of RION Vet, a veterinary biotechnology compa...
Back to Newsroom